Daiwa Securities Group Inc. Takes $1.27 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Daiwa Securities Group Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 20,400 shares of the medical equipment provider's stock, valued at approximately $1,269,000.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. The Manufacturers Life Insurance Company raised its position in shares of Lantheus by 3.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 242,449 shares of the medical equipment provider's stock valued at $16,845,000 after buying an additional 7,038 shares in the last quarter. Toroso Investments LLC raised its position in shares of Lantheus by 31.7% during the 3rd quarter. Toroso Investments LLC now owns 13,343 shares of the medical equipment provider's stock valued at $927,000 after buying an additional 3,210 shares in the last quarter. OLD National Bancorp IN raised its position in Lantheus by 15.5% in the 3rd quarter. OLD National Bancorp IN now owns 2,893 shares of the medical equipment provider's stock worth $201,000 after purchasing an additional 389 shares during the period. Comerica Bank raised its position in Lantheus by 122.2% in the 3rd quarter. Comerica Bank now owns 168,800 shares of the medical equipment provider's stock worth $11,728,000 after purchasing an additional 92,844 shares during the period. Finally, Deutsche Bank AG raised its position in Lantheus by 12.4% in the 3rd quarter. Deutsche Bank AG now owns 186,487 shares of the medical equipment provider's stock worth $12,957,000 after purchasing an additional 20,602 shares during the period. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling

In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now owns 62,898 shares of the company's stock, valued at $4,836,227.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now owns 62,898 shares of the company's stock, valued at $4,836,227.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.86, for a total transaction of $1,028,037.78. Following the completion of the transaction, the insider now directly owns 80,244 shares of the company's stock, valued at approximately $6,408,285.84. The disclosure for this sale can be found here. Insiders sold a total of 32,269 shares of company stock valued at $2,557,300 over the last 90 days. Insiders own 2.10% of the company's stock.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent analyst reports. SVB Leerink increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Thursday. Mizuho increased their price objective on shares of Lantheus from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, May 3rd. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Friday, May 3rd. B. Riley increased their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a "buy" rating in a research report on Thursday, April 18th. Finally, Truist Financial raised their target price on shares of Lantheus from $96.00 to $141.00 and gave the stock a "buy" rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $113.86.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded up $17.44 during midday trading on Thursday, reaching $123.62. The company had a trading volume of 5,961,692 shares, compared to its average volume of 1,047,057. The business's 50-day simple moving average is $81.01 and its 200 day simple moving average is $67.35. The stock has a market cap of $8.57 billion, a P/E ratio of 18.87 and a beta of 0.51. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $124.90. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The firm had revenue of $369.98 million during the quarter, compared to analysts' expectations of $349.46 million. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.